Drugs / XH001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07329894 | Feb 2026 → Aug 2027 expected | digestive system cancer | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07298200 | Dec 2025 → Jun 2028 expected | gastric cancer | Jia Wei | Recruiting | No outcome recorded |
| Phase 1 | NCT07594964 | Aug 2025 → Oct 2029 expected | biliary tract cancer, gastric cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma | Shenzhen Xinhe Biomedical | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07114666 | Aug 2025 → Aug 2029 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06353646 | Mar 2024 → Jun 2026 overdue | malignant pancreatic neoplasm | Wu Wenming | Recruiting | No outcome recorded |
| — | NCT05940181 | Mar 2023 → May 2025 | cancer | jianming xu | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XH001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05940181 ↗ |
| Modality | Vaccine | “XH001 (Neoantigen Cancer Vaccine)” NCT05940181 ↗ |